CollabRx and GeneInsight to Collaborate on Interpretation and Reporting Service for Clinical Genetic Sequencing

CollabRx and GeneInsight to Collaborate on Interpretation and Reporting
Service for Clinical Genetic Sequencing

SAN FRANCISCO and BOSTON, May 8, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc.
(Nasdaq:CLRX), a data analytics company focused on informing the clinical
interpretation of molecular diagnostic testing, and GeneInsight LLC., a
leading developer of software to support knowledge management and reporting
for genetic testing laboratories, today announced an agreement to deliver a
unique medical informatics solution to support the interpretation and
reporting of genetic variants from sequencing-based tests.

CollabRx and GeneInsight maintain that their joint initiative is designed to
establish a robust medical informatics solution to support genetic sequencing,
interpretation, and reporting in the clinical laboratory. GeneInsight has been
in use since 2005 and has supported the interpretation and reporting workflow
for more than 30,000 clinical genetic tests across multiple diagnostic
reference laboratories.

Under terms of the agreement, CollabRx medical and scientific content will be
made accessible through the GeneInsight knowledge management platform.
Initially focused on oncology, the combined offering will be available to the
clinical laboratory market.

"We are excited to work with GeneInsight to provide a key medical informatics
capability to the genetic testing laboratory market to accelerate adoption of
next generation sequencing-based tests for cancer and beyond," said Thomas R.
Mika, CollabRx Chairman, President and Chief Executive Officer. "Our
partnership with GeneInsight goes a long way towards enabling a truly
integrated clinical laboratory workflow."

Organizing and clinically interpreting genetic sequence data is among the
greatest challenges facing treating clinicians. The massive amount of
information is overwhelming physicians and limits their ability to utilize
genetic information to inform routine patient care, particularly for
oncology.The combined offering in oncology will enable clinical laboratories
to catalogue genetic variants from sequencing-based tests, and associate them
with CollabRx's expertly curated knowledge on available drugs and clinical
trials.Laboratories will have the option to incorporate this information into
reports for treating physicians to enable increasingly informed treatment
planning. Knowledge management, reporting and delivery of findings to ordering
clinicians will be streamlined through GeneInsight's networked infrastructure,
providing clinical laboratories the means to update physicians as knowledge
evolves so they can effectively manage patient care.

"The CollabRx and GeneInsight collaboration will enable laboratories using
GeneInsight to leverage CollabRx content as they draft reports explaining the
significance of variants identified in patients," said Heidi Rehm, PhD, Chief
Laboratory Director, Partners' Laboratory for Molecular Medicine. "When it
comes to diagnosing and developing treatments, we work closely with scientists
and clinicians at Massachusetts General Hospital and Brigham and Woman's
Hospital to advance patient care. We are thrilled to work with CollabRx and
its more than 75 leading independent clinical practitioners to accelerate
adoption of clinical sequencing in cancer."

About CollabRx

CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert
systems to inform healthcare decision-making. CollabRx uses information
technology to aggregate and contextualize the world's knowledge on
genomics-based medicine with specific insights from the nation's top cancer
experts, starting with the area of greatest need: advanced cancers in patients
who have effectively exhausted the standard of care. More information may be
obtained at

About GeneInsight

GeneInsight, LLC is a wholly-owned subsidiary of Partners HealthCare.
GeneInsight Suite® was developed by Partners HealthCare in collaboration with
leading geneticists, laboratory operations personnel, practicing physicians
and IT professionals. GeneInsight has been in clinical use since 2005 and has
supported the interpretation and reporting workflow for more than 30,000
clinical genetic tests across multiple diagnostic reference laboratories,
including the Partners HealthCare Laboratory for Molecular Medicine. More
information can be obtained at

About Partners HealthCare

Partners HealthCare is an integrated health system founded by Brigham and
Women's Hospital and Massachusetts General Hospital. In addition to its two
academic medical centers, the Partners system includes community and specialty
hospitals, a managed care organization, community health centers, a physician
network, home health and long-term care services, and other health-related
entities. Partners is one of the nation's leading biomedical research
organizations and a principal teaching affiliate of Harvard Medical
School.Partners HealthCare is a non-profit organization.

CollabRx Safe Harbor Statement

This press release includes forward-looking statements about CollabRx's
anticipated results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not limited to,
statements as to industry trends and CollabRx's plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by CollabRx with the Securities and Exchange Commission.
CollabRx undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.

CONTACT: CollabRx Contacts:
         Thomas R. Mika, CEO
         CollabRx, Inc.
         Robert Ferri Partners, LLC
         Robert Ferri
         (415) 575-1589 (direct)
         Partners Healthcare Contact
         Rich Copp

CollabRx, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.